Lundbeck A/S (VIE: LUNA), a Danish pharmaceutical company, has announced its intention to acquire U.S.-based Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) in a deal valued at USD 60.00 per share in cash. The transaction, on a fully diluted basis, is worth USD 2.6 billion in equity terms and USD 2.5 billion net of cash.
This strategic acquisition positions Lundbeck to gain access to bexicaserin, an investigational new 5-HT2C agonist being developed to treat epileptic seizures associated with Developmental and Epileptic Encephalopathies (DEEs). These conditions include Dravet syndrome, Lennox-Gastaut syndrome, and other rare forms of epilepsy. Bexicaserin, previously granted breakthrough therapy designation (BTD) in the United States, is currently the subject of a global Phase III clinical study involving subjects aged two and above with epileptic seizures associated with Dravet syndrome.
The acquisition underscores Lundbeck’s commitment to expanding its portfolio in the field of neurological disorders and enhancing its pipeline with innovative treatments for patients in need.- Flcube.com
